Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX) appointed Arati V. Rao, M.D., as chief medical officer to lead its clinical development organization.
Rao brings more than 20 years of experience in academic hematology and oncology, clinical development and global regulatory submissions. Her role includes overseeing clinical development as Nurix advances its registrational program for bexobrutideg and its broader pipeline. She joins from Pfizer, where she served as vice president, late-stage clinical development, and most recently as global franchise head for PF-08634404.
Nurix Therapeutics (NRIX) announced that company management will participate in fireside chats at three upcoming investor conferences.
The chats are scheduled for the UBS Global Biopharma Conference on November 17, 2026, at 2:40 p.m. GMT; the Jefferies Global Healthcare Conference on November 18, 2026, at 11:00 a.m. GMT; and the Piper Sandler Annual Healthcare Conference on December 2, 2026, at 3:30 p.m. ET. Live webcasts will be available through the Investors section of Nurix’s website, with archives available for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX) will present updated bexobrutideg trial data at the American Society of Hematology meeting on December 13, 2026. The ongoing Phase 1a/1b study evaluates the investigational drug, also called NX-5948, in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)—diseases that have returned or resisted treatment.
Efficacy data cover patients previously treated with covalent BTK inhibitors, drugs that block Bruton’s tyrosine kinase. Nurix describes the updated results as showing high response rates, durable clinical activity and favorable tolerability at the recommended Phase 2 dose of 600 mg once daily. No numerical response results are provided. Additional analyses at the meeting will cover patients without prior BTK inhibitor treatment, previously untreated patients and patients with high-risk molecular features.
Nurix Therapeutics (Nasdaq: NRIX) announced Sanofi’s decision to discontinue the Phase 1 trial of SAR448272 and terminate the STAT6 degrader program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties from that program. Eligibility for payments from other licensed Sanofi collaboration programs remains, with further development at Sanofi’s discretion.
Nurix’s cash runway guidance is unchanged: the company expects its $1.1 billion in cash, cash equivalents and marketable securities as of August 31, 2026, to fund operations into the second half of 2029. Its remaining clinical portfolio includes bexobrutideg in Phase 3 with Roche, NX-1607 in Phase 1b cohorts and GS-6791/NX-0479 in Phase 1 with Gilead.
Nurix Therapeutics (NRIX) reported third-quarter fiscal 2026 revenue of $673.1 million, driven primarily by its collaboration with Roche.
For the quarter ended August 31, revenue rose from $7.9 million a year earlier, including $653.2 million in Roche license revenue. Net income was $549.8 million, or $4.73 per diluted share, versus a $86.4 million loss. Following Roche’s $700 million upfront payment, cash, cash equivalents and marketable securities totaled $1.1 billion; Nurix expects runway into the second half of 2029.
The first patient was dosed in the Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Combination-study recruiting began, and NX-1607 expansion cohorts enrolled their first patient in September. Partner collaborations earned $27 million. Nurix discontinued further clinical development of NX-2127.
Nurix Therapeutics (Nasdaq: NRIX) enrolled the first patient in its Phase 1b/2 study combining bexobrutideg with venetoclax for chronic lymphocytic leukemia.
The NX-5948-203 study, conducted under Nurix's global collaboration with Roche, evaluates safety, tolerability and clinical activity. Bexobrutideg is an investigational oral drug that degrades Bruton’s tyrosine kinase; venetoclax is a standard-of-care treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma. The initial cohort focuses on disease that has returned or resisted treatment, with potential expansion to first-line treatment.
Nurix expects trial data to inform future development supporting registration across treatment lines, including combinations with rituximab and obinutuzumab in previously treated and untreated patients, and potential expansion into other B-cell malignancies.
Nurix Therapeutics (NRIX) and Gilead Sciences agreed to a second two-year research term extension for an undisclosed oncology program.
Nurix will receive a $10 million extension fee under the amended collaboration agreement, originally established in 2019. Gilead has an option to license resulting drug candidates. Nurix retains options for 50/50 U.S. profit and loss sharing on up to two programs, subject to restrictions. Exercising an option also entails sharing U.S. development costs and receiving reduced milestone payments, with royalties on sales outside the United States.
As of May 31, 2026, Nurix is eligible for up to approximately $1.3 billion in total payments tied to additional fees, payments and successful milestones. It is also eligible for tiered sales royalties. GS-6791 (NX-0479), the first program licensed by Gilead under the agreement, is now in Phase 1 clinical development.
Nurix Therapeutics (NRIX) achieved a $7 million research milestone under its collaboration with Pfizer to develop degrader antibody conjugates.
Nurix will receive the milestone payment, bringing its total receipts under the agreement to $82 million. The collaboration began with Seagen, now part of Pfizer, in September 2023. Nurix received $60 million upfront and is eligible for up to $3.4 billion in potential milestone payments across multiple programs. The agreement also provides mid-single-digit to low-double-digit percentage tiered royalties on future product sales.
Nurix Therapeutics (Nasdaq: NRIX) announced that its management will participate in fireside chats at several September 2026 investor conferences, including events hosted by Wells Fargo, H.C. Wainwright, Baird and Morgan Stanley, with sessions scheduled between September 8 and September 16, 2026.
The fireside chats will be webcast live and will be accessible via the Investors section of the Nurix website, where replays will be archived for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX) has appointed Wes Burwell as Chief Human Resources Officer and member of its Executive Management Team. He will lead the human resources function as Nurix advances its late-stage clinical pipeline in targeted protein degradation and prepares to transition into a fully integrated, commercial-stage biopharmaceutical organization.
According to the company, Burwell brings over 20 years of human resources leadership in life sciences, spanning research, clinical development and commercialization. His prior roles include vice president of human resources at Bolt Biotherapeutics and senior HR leadership positions at Global Blood Therapeutics, where he supported rapid organizational growth and the commercialization of a first therapy.